Todos Medical to Present at Upcoming Emerging Growth Conference

New York, NY, and Tel Aviv, ISRAEL – (NewMediaWire) – December 6, 2021 – Todos

Medical, Ltd. (OTCQB: TOMDF), a

comprehensive medical diagnostics and related solutions company, today

announced that Todos Medical will be presenting at the upcoming Emerging Growth

Conference to be held on December 8, 2021.

The following are details for

the conference:

Event: Emerging Growth Conference

Date: December 8, 2021

Location: On-Line

Time: Todos Medical Presentation at 3:00pm Eastern

Standard Time

This live, interactive online

event will give existing shareholders and the investment community the

opportunity to interact with the Company’s CEO, Gerald Commissiong, in real


Please register here to ensure

you are able to attend the conference and receive any updates that are


If attendees are not able to

join the event live on the day of the conference, an archived webcast will also

be made available on and we will also release a link to that

after the event.

About the Emerging Growth


The Emerging Growth conference is

an effective way for public companies to present and communicate their new

products, services and other major announcements to the investment community

from the convenience of their office, in a time efficient manner.

The Conference focus and

coverage includes companies in a wide range of growth sectors, with strong

management teams, innovative products & services, focused strategy,

execution, and the overall potential for long term growth. Its audience

includes potentially tens of thousands of Individual and Institutional

investors, as well as Investment advisors and analysts.

All sessions will be conducted

through video webcasts and will take place in the Eastern Time zone.

For more information, please

visit For more information

on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit

About Todos Medical Ltd.

Founded in Rehovot, Israel with

offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers

life-saving diagnostic solutions for the early detection of a variety of

cancers. In 2021, Todos completed the acquisition of U.S.-based medical

diagnostics company Provista Diagnostics, Inc. to gain rights to its

Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID

testing and Provista’s proprietary commercial-stage Videssa® breast cancer

blood test. The Company’s state-of-the-art and patented Todos Biochemical

Infrared Analyses (TBIA) is a proprietary cancer-screening technology using

peripheral blood analysis that deploys deep examination into cancer’s influence

on the immune system, looking for biochemical changes in blood mononuclear

cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1

and TMB-2, have received a CE mark in Europe. Todos is focused on the

commercialization of Videssa and will bring the TBIA tests to market


Todos has entered into a joint

venture with NLC Pharma targeting diagnostic and testing solutions to address

the COVID-19 pandemic. The Joint-Venture is pursuing the development of

diagnostic tests targeting the 3CL protease, as well as 3CL protease inhibitors

that target a fundamental reproductive mechanism of coronaviruses. The

Company’s proprietary therapeutic candidate Tollovir is currently in a Phase 2

clinical trial to treat hospitalized COVID-19 patients in Israel, and is

preparing to initiate Phase 2/3 clinical trials for both hospitalized and

non-hospitalized patients in Israel.

Todos is also developing blood

tests for the early detection of neurodegenerative disorders, such as

Alzheimer’s disease. The Lymphocyte Proliferation Test (LymPro Test) is a

diagnostic blood test that determines the ability of peripheral blood

lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic

stimulation that induces them to enter the cell cycle. It is believed that

certain diseases, most notably Alzheimer’s disease, are the result of

compromised cellular machinery that leads to aberrant cell cycle re-entry by

neurons, which then leads to apoptosis. LymPro is unique in the use of

peripheral blood lymphocytes as a surrogate for neuronal cell function,

suggesting a common relationship between PBLs and neurons in the brain.

Todos is also distributing

certain (COVID-19) testing materials and supplies to CLIA-certified labs in the

United States. The products cover multiple suppliers of PCR testing kits,

extraction kits, automation materials and supplies, as well as COVID-19

antibody and antigen testing kits.

For more information, please


Forward-looking Statements

Certain statements contained in

this press release may constitute forward-looking statements. For example,

forward-looking statements are used when discussing our expected clinical

development programs and clinical trials. These forward-looking statements are

based only on current expectations of management, and are subject to

significant risks and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements, including

the risks and uncertainties related to the progress, timing, cost, and results

of clinical trials and product development programs; difficulties or delays in

obtaining regulatory approval or patent protection for product candidates;

competition from other biotechnology companies; and our ability to obtain

additional funding required to conduct our research, development and

commercialization activities. In addition, the following factors, among others,

could cause actual results to differ materially from those described in the

forward-looking statements: changes in technology and market requirements;

delays or obstacles in launching our clinical trials; changes in legislation;

inability to timely develop and introduce new technologies, products and

applications; lack of validation of our technology as we progress further and

lack of acceptance of our methods by the scientific community; inability to

retain or attract key employees whose knowledge is essential to the development

of our products; unforeseen scientific difficulties that may develop with our

process; greater cost of final product than anticipated; loss of market share

and pressure on pricing resulting from competition; and laboratory results that

do not translate to equally good results in real settings, all of which could

cause the actual results or performance to differ materially from those

contemplated in such forward-looking statements. Except as otherwise required

by law, Todos Medical does not undertake any obligation to publicly release any

revisions to these forward-looking statements to reflect events or

circumstances after the date hereof or to reflect the occurrence of

unanticipated events. For a more detailed description of the risks and

uncertainties affecting Todos Medical, please refer to its reports filed from

time to time with the U.S. Securities and Exchange Commission.


Corporate and Investor Contact:

Richard Galterio

Todos Medical


Source link

The post Todos Medical to Present at Upcoming Emerging Growth Conference first appeared on Smallcaps Daily.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button